MicrobiologybioRxiv
Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy
DOI 10.1128/aac.00481-23
Author
N. C. Ammerman
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2018-2023 · peak 2/yrCo-Author Collaboration Network
10 top collaborators · 23 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship5 papers
Recent·Most cited
- MicrobiologybioRxiv
Differential in vitro activity of individual drugs and bedaquiline-rifabutin combinations against actively multiplying and nutrient-starved Mycobacterium abscessus
J. Lee, N. C. Ammerman, A. Agarwal…·E. Nuermberger
The paper evaluates the in vitro activity of drugs and drug combinations against different growth states of M. abscessus, finding that bedaquiline-rifabutin combinations show potent bactericidal effects.
DOI 10.1128/aac.02179-20 - MicrobiologybioRxiv
Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis
V. Saini, N. C. Ammerman, Y. S. Chang…·J. H. Grosset
This study tests a new TB treatment regimen combining high-dose rifapentine and clofazimine in mouse models, finding it more effective than either drug alone in shortening treatment duration.
DOI 10.1128/aac.00388-19 - MicrobiologybioRxiv
Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection
A. Kaushik, N. C. Ammerman, S. TYAGI…·K. Andries
This study evaluates a long-acting injectable bedaquiline formulation in a mouse model of latent tuberculosis, showing its efficacy with fewer doses compared to daily oral regimens.
DOI 10.1128/aac.00007-19 - MicrobiologybioRxiv
In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates
A. Kaushik, N. C. Ammerman, J. Lee…·E. Nuermberger
This study evaluates the in vitro activity of β-lactamase inhibitors relebactam and vaborbactam with β-lactams against MABC clinical isolates, showing improved anti-MABC activity.
DOI 10.1128/aac.02623-18